NDRA (ENDRA Life Sciences) EPS without NRI: $-7.21 (TTM As of Mar. 2026)


NDRA ENDRA Life Sciences Inc NDRA
25 GF Score
Price $5.61
! 2 Warning Signs
View Full Analysis

What is ENDRA Life Sciences EPS without NRI?

ENDRA Life Sciences NDRA +2.19% 25 EPS without NRI is $-7.21 as of Mar. 2026. GuruFocus rates NDRA with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 160 Medical Diagnostics & Research companies, ENDRA Life Sciences ranks better than 95.62% on this metric.

ENDRA Life Sciences's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-1.80. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-7.21.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for ENDRA Life Sciences's EPS without NRI or its related term are showing as below:

NDRA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.9   Med: 39.5   Max: 90.3
Current: 90.3

NDRA's 3-Year EPS without NRI Growth Rate is ranked better than
95.62% of 160 companies
in the Medical Diagnostics & Research industry
Industry Median: 10.95 vs NDRA: 90.30

ENDRA Life Sciences's EPS (Diluted) for the three months ended in Mar. 2026 was $-1.09. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.15.

ENDRA Life Sciences's EPS (Basic) for the three months ended in Mar. 2026 was $-1.09. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.15.


ENDRA Life Sciences  (NAS:NDRA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


ENDRA Life Sciences EPS without NRI Related Terms


ENDRA Life Sciences EPS without NRI Historical Data

* Premium members only.

The historical data trend for ENDRA Life Sciences's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ENDRA Life Sciences EPS without NRI Chart

ENDRA Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9,976.49 -7,980.00 -2,766.85 -52.99 -7.23

ENDRA Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.59 -1.80 -1.75 -1.86 -1.80

NDRA vs BIAF, ADVB, MBAI: EPS without NRI Comparison

For the Diagnostics & Research subindustry, ENDRA Life Sciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ENDRA Life Sciences PE Ratio without NRI vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where ENDRA Life Sciences's PE Ratio without NRI falls into.


NDRA
25GF Score
ENDRA Life Sciences Inc NDRA
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ENDRA Life Sciences EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-7.21 mean?
ENDRA Life Sciences (NDRA) has a EPS without NRI of $-7.21 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on ENDRA Life Sciences and its competitors. According to the industry distribution chart, ENDRA Life Sciences ranks #7 out of 160 companies in the Medical Diagnostics & Research industry, placing it in the top 4.4%.
Is ENDRA Life Sciences' EPS without NRI too high?
ENDRA Life Sciences' current EPS without NRI is $-7.21. Based on the distribution chart, ENDRA Life Sciences ranks #7 out of 160 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, ENDRA Life Sciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ENDRA Life Sciences' EPS without NRI compare to BIAF and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, ENDRA Life Sciences ranks #7 out of 160 companies for EPS without NRI. This places ENDRA Life Sciences in the top 4% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 10.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.95, based on 160 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on ENDRA Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENDRA Life Sciences's current EPS without NRI is $-7.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENDRA Life Sciences stock overvalued right now?
ENDRA Life Sciences (NDRA) has a current EPS without NRI of $-7.21. The current EPS without NRI is $-7.21. ENDRA Life Sciences' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For ENDRA Life Sciences (NDRA), the current EPS without NRI is $-7.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ENDRA Life Sciences Business Description

Address 3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
25GF Score

Get the complete analysis for NDRA

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.61
Price